Newsletter

028300 - HLB Co., Ltd.

028300 Summary
Biopharma
Stock Price & Overview
₩33,750 +950 (+2.90%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩33,750  ≈ US$24  ·  Market cap ₩4.5tn (≈ $3.2bn)
What kstock analysis is. It reads the Korean news and the DART filing, checks the numbers against the source, and explains what changed and what to watch. It does not issue buy, sell or hold ratings and it does not set price targets. Why not »

028300 Analysis

ks

HLB: Rivoceranib Optionality Cannot Hide A ₩121.3bn Half-Year Loss

HLB Co., Ltd. remains a rivoceranib approval story, while its small operating businesses cannot yet support the company's market value.

kstock researchYesterday, 1:46 PMBiopharmaSave
1 piece. Written with AI assistance from Korean-language sources; each links the article it rests on.

Similar to 028300

SymbolLast Price
326030SK biopharmaceuticals Co., Ltd.₩86,600
+0.2%
128940Hanmi Pharm. Co., Ltd.₩473,500
+2.8%
000100Yuhan Corporation₩81,400
+0.0%
298380ABL Bio Inc.₩71,400
+5.6%
000250Samchundang Pharm₩157,000
+1.0%
087010Peptron, Inc.₩157,300
+7.3%
141080LigaChem Biosciences Inc.₩92,000
+4.2%
145020Hugel, Inc.₩244,000
+1.5%
302440SK Bioscience Co., Ltd.₩37,900
+0.4%
009420Hanall Biopharma Co., Ltd.₩54,700
+1.5%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.